Editor’s note: This article is written by Elizaveta Bannova, a billing specialist at WCH, based on publicly available FDA documents and industry research.
I recently came across a case that made me think about how easily providers can fall into the trap of beautiful promises from suppliers. The FDA Warning Letter issued to BioLab Sciences in August 2022 serves as a stark reminder of what can go wrong when due diligence takes a backseat to sales pitches.
When Beautiful Promises Turn Into Legal Nightmares
BioLab Sciences manufactured an entire line of products: Fluid GF™, Restore GF™, Fluid Flow™, Amnio Restore™, Stimuleyes™, MyOwnSkin™, and MySkinRestore™. According to publicly available FDA documents, suppliers marketed these as revolutionary wound treatment methods and advanced therapeutic solutions. What they didn’t emphasize was that none of these products had valid FDA approval.
The FDA Warning Letter dated August 23, 2022, revealed that BioLab Sciences had been manufacturing and distributing biological products without the required Biologics License Application (BLA) or Investigational New Drug (IND) application. This isn’t just a paperwork issue—it’s a fundamental violation of federal law that can have serious consequences for everyone involved.
The Legal Reality: It’s Not Just About Money
Here’s what many providers don’t realize: using unapproved biological products can expose you to more than just financial losses. Under federal law, knowingly using unapproved drugs or biologics can result in:
- Criminal charges under the Federal Food, Drug, and Cosmetic Act
- Civil penalties that can reach hundreds of thousands of dollars
- Professional licensing actions by state medical boards
- Exclusion from federal healthcare programs like Medicare and Medicaid
Even if you were misled by a supplier, proving that you conducted proper due diligence becomes crucial for your defense. The legal standard often comes down to: “What should a reasonable healthcare provider have known?”
Beyond Legal Compliance: The Ethical Imperative
As healthcare providers, you take an oath to “first, do no harm.” When you use products that haven’t undergone proper FDA review, you’re essentially making patients unwitting participants in uncontrolled experiments.
Consider what the FDA found at BioLab Sciences:
- Products claimed to be sterile were processed without validated sterilization
- Research-only components were used in products for human treatment
- No proper testing supported the claimed shelf life of products
- Manufacturing areas had significant contamination issues
Every patient who received these products was potentially exposed to contaminated, ineffective, or harmful treatments. That’s not just a regulatory violation—it’s a fundamental breach of the trust patients place in us.
BioLab Sciences’ Response: Too Little, Too Late
The FDA Warning Letter reveals that BioLab Sciences provided multiple written responses between September 2021 and July 2022. However, the FDA determined these responses were “inadequate to address our concerns.”
According to the letter, the company did commit to:
- Voluntarily cease manufacturing MyOwnSkin™ and MySkinRestore™
- Discontinue several other products including Stimuleyes™ and Fluid Flow™
- Continue marketing only certain amniotic membrane and fluid products
But notably, the company failed to address the fundamental issue: they continued marketing biological products without proper FDA approval. Their responses didn’t adequately explain how they would obtain the required BLAs or INDs for their remaining products.
This pattern—acknowledging some problems while continuing questionable practices—is unfortunately common in the industry. It’s exactly why providers can’t rely on supplier assurances alone.
What Providers Need to Do
Immediate Actions (This Week)
Audit Your Current Inventory
- List all biological products currently in use
- Identify the manufacturer and specific product names
- Check FDA databases for approval status
- Quarantine any products without clear approval
Verify Supplier Claims
- Request BLA or IND numbers for all biological products
- Don’t accept “FDA compliant” or “follows FDA guidelines” as sufficient
- Verify numbers directly through FDA databases, not supplier documentation
Short-Term Actions (Next 30 Days)
Establish Verification Protocols
- Create a checklist for evaluating new biological products
- Require FDA approval documentation before any purchase
- Train staff on red flags in supplier presentations
- Develop relationships with compliance-focused suppliers
Review Patient Records
- Identify patients who received questionable products
- Document any adverse events or treatment failures
- Consult with legal counsel about disclosure obligations
- Consider patient notification if safety concerns exist
Ongoing Monitoring (Quarterly)
Stay Current with FDA Actions
- Monitor FDA Warning Letters in your specialty area
- Subscribe to FDA safety alerts and recalls
- Review the approval status of products in your inventory
- Update protocols based on new regulatory guidance
Supplier Relationship Management
- Conduct regular compliance reviews with suppliers
- Request updated approval documentation annually
- Diversify suppliers to reduce dependency risks
- Share compliance expectations clearly with sales representatives
Red Flags That Should Stop You Cold
After reviewing the BioLab Sciences case and similar FDA actions, here are warning signs that should immediately raise concerns:
- Evasive answers about FDA approval status
- Multiple product names for what appears to be the same product
- Claims about “breakthrough” technology without peer-reviewed validation
- Pressure to purchase quickly or in large quantities
- Pricing is significantly below market rates for similar approved products
- Marketing for multiple unrelated conditions with a single product
Industry Accountability
The BioLab Sciences case isn’t isolated. A review of recent FDA Warning Letters shows a troubling pattern of companies cutting corners on regulatory compliance while aggressively marketing to healthcare providers.
These companies often target busy practitioners who don’t have time for extensive regulatory research. They rely on the assumption that providers will trust their claims rather than independently verify approval status.
But here’s the reality: ignorance isn’t a defense when patients are harmed or when regulatory agencies investigate. The responsibility for ensuring product safety ultimately rests with the prescribing provider.
Building a Culture of Verification
The medical device and biologics industry will continue to evolve, and legitimate innovations will emerge. That’s exciting for patient care, but it also means providers need to build robust verification systems.
Consider implementing these cultural changes in your practice:
- Make FDA verification a standard part of product evaluation
- Encourage staff to ask tough questions of suppliers
- Reward thorough due diligence over quick purchasing decisions
- Share regulatory information with colleagues and professional networks
Remember: legitimate companies with properly approved products will welcome your verification efforts. They understand that regulatory compliance is essential for patient safety and practice sustainability.
Your Professional Duty
The BioLab Sciences case serves as a crucial reminder that our first obligation is to our patients’ well-being. When we use products that haven’t undergone proper FDA review, we’re not just risking regulatory violations—we’re potentially compromising patient safety and violating the fundamental trust that makes healthcare possible.
Don’t let persuasive sales presentations override your professional judgment. Take the time to verify. Check the databases. Ask the hard questions. Your patients—and your practice—deserve products that meet the highest regulatory and safety standards.
The cost of verification is measured in time and effort. The cost of not verifying can be measured in patient harm, legal consequences, and professional reputation. The choice should be clear.
Sources:
- FDA Warning Letter to BioLab Sciences, Inc., MARCS-CMS 648658, August 23, 2022
- FDA Center for Biologics Evaluation and Research (CBER) regulatory guidance
- Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 321 et seq.
- Public Health Service Act, 42 U.S.C. § 262
- 21 CFR Part 1271 – Human Cells, Tissues, and Cellular and Tissue-Based Products
- FDA Orange Book database and biologics approval records
***This analysis is based on publicly available FDA documents and regulatory guidance. Individual cases may vary, and providers should consult with legal counsel for specific compliance questions.
Discover more from Doctor Trusted
Subscribe to get the latest posts sent to your email.
